Artificial Intelligence
Metabolic Disorders Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030
New York, Feb. 25, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Metabolic Disorders Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030” – https://www.reportlinker.com/p06027739/?utm_source=GNW
16 billion in 2020 to $146.25 billion in 2021 at a compound annual growth rate (CAGR) of 2.2%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $198.07 billion in 2025 at a CAGR of 8%.
The metabolic disorders drugs market consists of sales of metabolic disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce metabolic disorders drugs to treat metabolic diseases.This industry includes establishments that produce drugs such as insulin, pramlintide and other drugs to treat diabetes, anti-thyroid drugs to treat hyperthyroidism, and other drugs to treat pituitary gland, adrenal gland and parathyroid gland disorders.
The metabolic disorders drugs market is segmented into anti diabetic drugs; anti-thyroid drugs; and others (hyperparathyroidism, hypopituitarism, hypoadrenalism).
North America was the largest region in the global metabolic disorders drugs market, accounting for 54% of the market in 2020.Asia Pacific was the second largest region accounting for 24% of the global metabolic disorders drugs market.
Africa was the smallest region in the global metabolic disorders drugs market.
Companies are focusing on employing artificial intelligence applications to revolutionize the treatment of metabolic disorders.Artificial Intelligence is a machine-based learning which makes use of human intelligence functionalities like reasoning and problem-solving abilities to obtain insights and provide useful information.
This technology radically changes the treatment of metabolic syndrome by analyzing large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. 3BIGS, a Korean biodata analysis-based company that studies the relation between diseases, targets and drugs is using AI technology to help researches repurpose the drugs for additional diseases.
Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period.Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs.
Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the metabolic disorders drugs industry in the historic period.
The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as diabetes and obesity.Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of metabolic disorders.
According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. These factors are expected to increase the patient pool globally, thereby driving the metabolic disorders drugs market during the forecast period.
Read the full report: https://www.reportlinker.com/p06027739/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
__________________________
Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001